Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia CorpfiledCriticalPharmacia Corp
Priority to CU20040177ApriorityCriticalpatent/CU23368A3/en
Publication of CU23368A3publicationCriticalpatent/CU23368A3/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se describen compuestos de la Fórmula: y sus sales farmacéuticamente aceptables en los que R1, R2, R3, R4 y R5 se definen en la presente. Estos compuestos son útiles para tratar enfermedades y afecciones causadas o exacerbadas por la actividad de p38 MAP quinasa desregulada y/o ENT. También se describen composiciones farmacéuticas que contienen los compuestos, métodos para preparar los compuestos y métodos de tratamiento que utilizan los compuestos.Compounds of the Formula are described: and their pharmaceutically acceptable salts in which R1, R2, R3, R4 and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by the activity of deregulated p38 MAP kinase and / or ENT. Pharmaceutical compositions containing the compounds, methods for preparing the compounds and treatment methods using the compounds are also described.
DERIVATIVES OF 5-PHENYL-4-METHYL-TIAZOL-2-IL-AMINA AS INHIBITORS OF KINASA ENZYMES PHOSFATIDILINOSITOL 3 (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE RESPIRATORY ROUTES
COMPOUNDS DERIVED FROM TIAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OF DISEASES MEDIATED BY DOSFATIDILNOSITOL 3-KINASE SUCH AS RESPIRATORY DISEASES, ALLERGIES, Rheumatoid Arthritis, OSTEOA